Measurable residual disease conversion rate with consolidation chemotherapy in acute myeloid leukemia

References

• Freeman SD, Hills RK, Virgo P, et al. Measurable residual disease at induction redefines partial response in acute myeloid leukemia and stratifies outcomes in patients at standard risk without NPM1 mutations. J Clin Oncol. 2018;36(15):1486–1497. doi:10.1200/JCO.2017.76.3425
   PubMed Web of Science ®Google Scholar
• Walter RB, Othus M, Burnett AK, et al. Resistance prediction in AML: analysis of 4601 patients from MRC/NCRI, HOVON/SAKK, SWOG and MD Anderson Cancer Center. Leukemia. 2015;29(2):312–320. doi:10.1038/leu.2014.242
   PubMed Web of Science ®Google Scholar
• Araki D, Wood BL, Othus M, et al. Allogeneic hematopoietic cell transplantation for acute myeloid leukemia: time to move toward a minimal residual Disease-Based definition of complete remission? J Clin Oncol. 2016;34(4):329–336. doi:10.1200/JCO.2015.63.3826
   PubMed Web of Science ®Google Scholar
• Döhner H, Wei AH, Appelbaum FR, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140(12):1345–1377. doi:10.1182/BLOOD.2022016867
   PubMed Web of Science ®Google Scholar
• Ravandi F, Walter RB, Freeman SD. Evaluating measurable residual disease in acute myeloid leukemia. Blood Adv. 2018;2(11):1356–1366. doi:10.1182/bloodadvances.2018016378
   PubMed Web of Science ®Google Scholar
• Gaut D, Mead M. Measurable residual disease in hematopoietic stem cell transplantation-eligible patients with acute myeloid leukemia: clinical significance and promising therapeutic strategies. Leuk Lymphoma. 2021;62(1):8–31. doi:10.1080/10428194.2020.1827251
   PubMed Web of Science ®Google Scholar
• Heuser M, Freeman SD, Ossenkoppele GJ, et al. 2021 Update on MRD in acute myeloid leukemia: a consensus document from the european LeukemiaNet MRD working party. Blood. 2021;138(26):2753–2767. doi:10.1182/BLOOD.2021013626
   PubMed Web of Science ®Google Scholar
• Freeman SD, Virgo P, Couzens S, et al. Prognostic relevance of treatment response measured by flow cytometric residual disease detection in older patients with acute myeloid leukemia. J Clin Oncol. 2013;31(32):4123–4131. doi:10.1200/JCO.2013.49.1753
   PubMed Web of Science ®Google Scholar
• Zhou Y, Othus M, Araki D, et al. Pre- and post-transplant quantification of measurable ('minimal’) residual disease via multiparameter flow cytometry in adult acute myeloid leukemia. Leukemia. 2016;30(7):1456–1464. doi:10.1038/leu.2016.46
   PubMed Web of Science ®Google Scholar
• Terwijn M, van Putten WL, Kelder A, et al. High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study. J Clin Oncol. 2013;31(31):3889–3897. doi:10.1200/JCO.2012.45.9628\rJCO.2012.45.9628[pii]
   PubMed Web of Science ®Google Scholar
• Kern W, Voskova D, Schoch C, et al. Determination of relapse risk based on assessment of minimal residual disease during complete remission by multiparameter flow cytometry in unselected patients with acute myeloid leukemia. Blood. 2004;104(10):3078–3085. doi:10.1182/blood-2004-03-1036
   PubMed Web of Science ®Google Scholar
• Buckley SA, Wood BL, Othus M, et al. Minimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a meta-analysis. Haematologica. 2017;102(5):865–873. doi:10.3324/haematol.2016.159343
   PubMed Web of Science ®Google Scholar
• Balsat M, Renneville A, Thomas X, et al. Postinduction minimal residual disease predicts outcome and benefit from allogeneic stem cell transplantation in acute myeloid leukemia with NPM1 mutation: a study by the acute leukemia french association group. J Clin Oncol. 2017;35(2):185–193. doi:10.1200/JCO.2016.67.1875
   PubMed Web of Science ®Google Scholar
• Dillon LW, Gui G, Page KM, et al. DNA sequencing to detect residual disease in adults with acute myeloid leukemia prior to hematopoietic cell transplant. JAMA. 2023;329(9):745–755. doi:10.1001/JAMA.2023.1363
   PubMed Web of Science ®Google Scholar
• Platzbecker U, Middeke JM, Sockel K, et al. Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial. Lancet Oncol. 2018;19(12):1668–1679. doi:10.1016/S1470-2045(18)30580-1
   PubMed Web of Science ®Google Scholar
• Döhner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424–447. doi:10.1182/blood-2016-08-733196
   PubMed Web of Science ®Google Scholar
• Appelbaum J, Loeb A, Gardner K, et al. Additional cytotoxic chemotherapy is unlikely to eliminate measurable residual acute myeloid leukemia (AML). Blood. 2019;134(Supplement_1):260–260. doi:10.1182/blood-2019-131678
   Google Scholar
• Bataller A, Oñate G, Diaz-Beyá M, et al. Acute myeloid leukemia with NPM1 mutation and favorable european LeukemiaNet category: outcome after preemptive intervention based on measurable residual disease. Br J Haematol. 2020;191(1):52–61. doi:10.1111/BJH.16857
   PubMed Web of Science ®Google Scholar
• Venditti A, Buccisano F, Del Poeta G, et al. Level of minimal residual disease after consolidation therapy predicts outcome in acute myeloid leukemia. Blood. 2000;96(12):3948–3952. http://www.ncbi.nlm.nih.gov/pubmed/11090082 doi:10.1182/blood.V96.12.3948.h8003948_3948_3952
   PubMed Web of Science ®Google Scholar
• Buccisano F, Maurillo L, Gattei V, et al. The kinetics of reduction of minimal residual disease impacts on duration of response and survival of patients with acute myeloid leukemia. Leukemia. 2006;20(10):1783–1789. doi:10.1038/sj.leu.2404313
   PubMed Web of Science ®Google Scholar
• Murdock HM, Kim HT, Denlinger N, et al. Impact of diagnostic genetics on remission MRD and transplantation outcomes in older patients with AML. Blood. 2022;139(24):3546–3557. doi:10.1182/BLOOD.2021014520
   PubMed Web of Science ®Google Scholar
• Tsai CH, Tang JL, Tien FM, et al. Clinical implications of sequential MRD monitoring by NGS at 2 time points after chemotherapy in patients with AML. Blood Adv. 2021;5(10):2456–2466. doi:10.1182/BLOODADVANCES.2020003738
   PubMed Web of Science ®Google Scholar
• Thol F, Gabdoulline R, Liebich A, et al. Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML. Blood. 2018;132(16):1703–1713. doi:10.1182/BLOOD-2018-02-829911
   PubMed Web of Science ®Google Scholar
• Hourigan CS, Dillon LW, Gui G, et al. Impact of conditioning intensity of allogeneic transplantation for acute myeloid leukemia with genomic evidence of residual disease. J Clin Oncol. 2020;38(12):1273–1283. doi:10.1200/JCO.19.03011
   PubMed Web of Science ®Google Scholar
• Norkin M, Katragadda L, Zou F, et al. Minimal residual disease by either flow cytometry or cytogenetics prior to an allogeneic hematopoietic stem cell transplant is associated with poor outcome in acute myeloid leukemia. Blood Cancer J. 2017;7(12):634. doi:10.1038/s41408-017-0007-x
   PubMedGoogle Scholar
• Marcucci G, Mrózek K, Ruppert AS, et al. Abnormal cytogenetics at date of morphologic complete remission predicts short overall and disease-free survival, and higher relapse rate in adult acute myeloid leukemia: results from cancer and leukemia group B study 8461. J Clin Oncol. 2004;22(12):2410–2418. doi:10.1200/JCO.2004.03.023
   PubMed Web of Science ®Google Scholar
• Chen Y, Cortes J, Estrov Z, et al. Persistence of ­cytogenetic abnormalities at complete remission ­after induction in patients with acute myeloid ­leukemia: prognostic significance and the potential role of allogeneic stem-cell transplantation. J Clin Oncol. 2011;29(18):2507–2513. doi:10.1200/JCO.2010.34.2873
   PubMed Web of Science ®Google Scholar
• Stahl M, Derkach A, Farnoud N, et al. Molecular predictors of immunophenotypic measurable residual disease clearance in acute myeloid leukemia. Am J Hematol. 2023;98(1):79–89. doi:10.1002/AJH.26757
   PubMed Web of Science ®Google Scholar